Extracellular Vesicles Derived from FGF2-Primed Astrocytes Against Mitochondrial and Synaptic Toxicities in Parkinson’s Disease
International Journal of Nanomedicine · 2025-04 · Volume 20 · 4627-4644
DOI: 10.2147/ijn.s511474 ↗At a glance
Journal article in International Journal of Nanomedicine, 2025-04. Written by Xiaomin Wen and 7 co-authors. Institution: College of Life Sciences, Northwest University, Xi'an, Shaanxi, 710069, People's Republic of China. Major MEDLINE topics: Astrocytes, Extracellular Vesicles, Mitochondria, Fibroblast Growth Factor 2. Cited 14 times so far (Crossref). The full text is freely available (open access, CC BY-NC 3.0).
Abstract (original language)
Purpose
Mitochondrial dysfunction associated with neuronal degeneration and subsequent synaptic disconnection are essential for the development of Parkinson's disease (PD). Considering that astrocytes play key roles in synaptogenesis during development, we hypothesized that fibroblast growth factor - 2 (FGF2), a key factor for astrocyte development, could reverse the toxic phenotype of reactive astrocytes, and the extracellular vesicles (EVs) derived from FGF2-primed astrocytes would enhance synaptogenesis in PD model. The present study was to test this hypothesis.
Methods
EVs isolated from FGF2-primed astrocytes (FGF2-EVs) were characterized by transmission electron microscopy and nanoparticle tracking analysis. FGF2-EVs were applied to both in vitro and in vivo models of PD. EVs derived from naïve astrocytes (CON-EV) were used as control. Mitochondrial alterations, neuronal survival, synaptogenesis, and mice behavior were subsequently evaluated by quantitative real-time polymerase chain reaction, Western-blotting, immunohistochemistry, and CatWalk gait analysis. To dissect the underlying mechanisms, proteomic analysis and small interfering RNA (siRNA) mediated gene silencing were adopted.
Results
FGF2 treatment restored the expression of neural progenitor markers and suppressed the levels of A1 astrocytic markers in MPP+ pretreated astrocytes. FGF2-EVs, in comparison with that of CON-EVs, effectively protected neurons from mitochondrial fragmentation and stimulated synaptogenesis, as evidenced by expression of Mitofusin 2 (Mfn2), postsynaptic density protein 95 (PSD-95) and synaptophysin (SYP). Proteomic analysis revealed high enrichment of neural cell adhesion molecule 1 (NCAM1) in FGF2-EVs. Knocking down NCAM1 severely influenced the expression of mitochondrial and synaptic proteins. Furthermore, delivery of FGF2-EVs significantly enhanced the survival of TH+ neurons, the levels of NCAM1 and synaptogenesis in the substantia nigra of PD mice, as well as the locomotion of PD mice.
Conclusion
EVs from FGF2-primed astrocytes are superior in protecting PD mice against mitochondrial and synaptic toxicities, possibly through NCAM1, which could be used as a therapeutic strategy for PD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Life Sciences, Northwest University, Xi'an, Shaanxi, 710069, People's Republic of China.
- Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China.
ORCID profiles: Shengxi Wu
Cite
APA
Wen, X., Cao, W., Ding, H., Chen, A., Sun, Z., Wang, Y., Xi, Y., & Wu, S. (2025). Extracellular Vesicles Derived from FGF2-Primed Astrocytes Against Mitochondrial and Synaptic Toxicities in Parkinson’s Disease. International Journal of Nanomedicine, Volume 20, 4627-4644. https://doi.org/10.2147/ijn.s511474
Vancouver
Wen X, Cao W, Ding H, Chen A, Sun Z, Wang Y, et al. Extracellular Vesicles Derived from FGF2-Primed Astrocytes Against Mitochondrial and Synaptic Toxicities in Parkinson’s Disease. International Journal of Nanomedicine. 2025;Volume 20:4627-4644. doi:10.2147/ijn.s511474
BibTeX
@article{Wen2025,
author = {Wen, Xiaomin and Cao, Wanjun and Ding, Hui and Chen, Andi and Sun, Zhichuan and Wang, Yazhou and Xi, Ye and Wu, Shengxi},
title = {Extracellular Vesicles Derived from FGF2-Primed Astrocytes Against Mitochondrial and Synaptic Toxicities in Parkinson’s Disease},
journal = {International Journal of Nanomedicine},
year = {2025},
volume = {Volume 20},
pages = {4627--4644},
doi = {10.2147/ijn.s511474}
}
EUVIMED